Learn about this study
This Phase 1/2 study investigates TLX101 for the treatment of newly diagnosed glioblastoma. The trial aims to evaluate the safety and efficacy of this novel radioligand therapy in patients with this aggressive brain cancer
Who can participate?
Participating in clinical research is a significant, personal decision. Before enrolling, the study team will fully explain the research and provide an Informed Consent Form that outlines possible benefits and risks. This is your chance to ask questions and consult with your doctor to determine if the study is right for you.
You may be able to participate if:
- Have histologically confirmed intracranial glioblastoma following surgical resection.
- Have not had prior treatment for glioma, excluding surgery.
- You meet other specific inclusion criteria set by the study
Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.